Fred Aslan - 02 Nov 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ARTV
Reported as of: 02 Nov 2026
Net transaction value: -$259,972
SEC form: 4
Accepted by SEC: 03 Nov 2026, 16:04:26 UTC
Prior SEC filing: 07 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Bush, Attorney-in-Fact

Filing notes and source

Key filing fact

Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 03 Nov 2026.

Key facts

This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Nov 2026, 16:04.

Change

Previous filing in this sequence was filed on 07 Oct 2026.
Current net transaction value: -$259,972.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001909362 Primary reporting owner

Aslan Fred

Relationship: Chief Executive Officer, Director
Address: C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Jennifer Bush, Attorney-in-Fact
Signature date: 03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTV transaction

Common Stock

Sale

Transaction value: -$259,972
Shares: -62,178
Change %: -4.1%
Price: $4.18
Shares after: 1,457,428
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.